Natural killer cell p44-related receptor ligands (NKp44L)

NKp44 ligands (NKp44L) are a heterogeneous group of molecules expressed on the surface of tumor cells and virus-infected cells that serve as binding partners for the NKp44 (NCR2) receptor on activated natural killer (NK) cells. These ligands include diverse proteins such as the activating isoform of MLL5, the inhibitory nuclear protein PCNA (when translocated to the cell surface), and soluble factors like PDGF-DD and Nidogen-1. In viral contexts, NKp44 recognizes pathogen-encoded proteins including influenza hemagglutinin and flavivirus envelope glycoproteins. The interaction between NKp44 and its ligands plays a dual role in immunity: activating ligands trigger NK cell-mediated lysis and the secretion of proinflammatory cytokines like IFN-gamma, whereas inhibitory ligands like PCNA can suppress NK cell activity to facilitate tumor immune evasion. Viral infections can also modulate the expression of cellular NKp44 ligands or produce viral proteins that directly engage the receptor to either trigger or evade immune detection. Therapeutic strategies targeting these ligands are currently in development, including NKp44-based chimeric antigen receptor (CAR) therapies and monoclonal antibodies designed to disrupt inhibitory signaling or specifically eliminate cells expressing tumor-associated NKp44L.

Other names

NKp44 ligandsNCR2 ligandsNatural cytotoxicity receptor 2 ligandsTumor-associated NKp44 ligandsViral NKp44 ligands

Binding of activating ligands to the NKp44 receptor triggers natural killer cell cytotoxicity and cytokine release, while inhibitory ligands like PCNA suppress immune activity; therapeutic agents either block inhibitory interactions or utilize NKp44-based chimeric receptors to target ligand-expressing cells.